Thymic Carcinoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Thymic Carcinoma – Pipeline Review, H2 2016’, provides an overview of the Thymic Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thymic Carcinoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thymic Carcinoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Thymic Carcinoma

The report reviews pipeline therapeutics for Thymic Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Thymic Carcinoma therapeutics and enlists all their major and minor projects

The report assesses Thymic Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Thymic Carcinoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Thymic Carcinoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Thymic Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Merck & Co., Inc.

Novartis AG

Onxeo SA

Sumitomo Dainippon Pharma Co., Ltd.

Taiwan Liposome Company, Ltd.

Tiziana Life Sciences Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Thymic Carcinoma Overview 6

Therapeutics Development 7

Pipeline Products for Thymic Carcinoma - Overview 7

Pipeline Products for Thymic Carcinoma - Comparative Analysis 8

Thymic Carcinoma - Therapeutics under Development by Companies 9

Thymic Carcinoma - Therapeutics under Investigation by Universities/Institutes 10

Thymic Carcinoma - Pipeline Products Glance 11

Clinical Stage Products 11

Thymic Carcinoma - Products under Development by Companies 12

Thymic Carcinoma - Products under Investigation by Universities/Institutes 13

Thymic Carcinoma - Companies Involved in Therapeutics Development 14

Merck & Co., Inc. 14

Novartis AG 15

Onxeo SA 16

Sumitomo Dainippon Pharma Co., Ltd. 17

Taiwan Liposome Company, Ltd. 18

Tiziana Life Sciences Plc 19

Thymic Carcinoma - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

amrubicin hydrochloride - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

belinostat - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

milciclib - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

pasireotide ER - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

pembrolizumab - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

TLC-388 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Vaccine to Target WT1 for Oncology - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Thymic Carcinoma - Product Development Milestones 85

Featured News & Press Releases 85

Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014 85

May 14, 2014: Phase II data of Nerviano Medical Science’s kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO 85

Appendix 86

Methodology 86

Coverage 86

Secondary Research 86

Primary Research 86

Expert Panel Validation 86

Contact Us 86

Disclaimer 87

List of Tables

List of Tables

Number of Products under Development for Thymic Carcinoma, H2 2016 7

Number of Products under Development for Thymic Carcinoma – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Products under Investigation by Universities/Institutes, H2 2016 13

Thymic Carcinoma – Pipeline by Merck & Co., Inc., H2 2016 14

Thymic Carcinoma – Pipeline by Novartis AG, H2 2016 15

Thymic Carcinoma – Pipeline by Onxeo SA, H2 2016 16

Thymic Carcinoma – Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 17

Thymic Carcinoma – Pipeline by Taiwan Liposome Company, Ltd., H2 2016 18

Thymic Carcinoma – Pipeline by Tiziana Life Sciences Plc, H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

List of Figures

List of Figures

Number of Products under Development for Thymic Carcinoma, H2 2016 7

Number of Products under Development for Thymic Carcinoma – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Top 10 Targets, H2 2016 21

Number of Products by Stage and Top 10 Targets, H2 2016 21

Number of Products by Mechanism of Actions, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared